March 23, 2020 / 12:55 PM / in 7 days

BRIEF-Abbvie - VIALE-A Trial Of Venclexta In Combination With Azacitidine Versus Azacitidine In Combination With Placebo Met Its Dual Primary Endpoints

March 23 (Reuters) - Abbvie Inc:

* ABBVIE INC - VIALE-A TRIAL OF VENCLEXTA IN COMBINATION WITH AZACITIDINE VERSUS AZACITIDINE IN COMBINATION WITH PLACEBO MET ITS DUAL PRIMARY ENDPOINTS

* ABBVIE - VIALE-A STUDY DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINTS OF OVERALL SURVIVAL, COMPOSITE COMPLETE REMISSION RATE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below